{name}
{subtitle}
A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer
city
~16 mi. (Wuhu, China, +107 more cities)
facility
Yijishan Hospital of Wannan Medical College
drug
abemaciclib, +2 more drugs
drug type
hormone therapy, +1 more type
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~92 mi. (Jinan, China, +192 more cities)
facility
Jinan Central Hospital
biomarker
ER Positive, +1 more biomarker
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~92 mi. (Jinan, China, +247 more cities)
facility
Local Institution
biomarker
ER Positive, +1 more biomarker
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
city
~92 mi. (Jinan, China, +271 more cities)
facility
Local Institution
drug
docetaxel, +2 more drugs
drug type
chemotherapy, +2 more types
A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
city
~92 mi. (Jinan, China, +127 more cities)
facility
Jinan Central Hospital
drug
cetuximab, +3 more drugs
drug type
chemotherapy, +1 more type
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)
city
~92 mi. (Jinan, China, +122 more cities)
facility
Shandong Province Cancer Hospital ( Site 3100)
drug
etoposide, +5 more drugs
drug type
chemotherapy, +3 more types
Study Assessing the Efficacy and Safety of Alpelisib + Nab-paclitaxel in Subjects With Advanced TNBC Who Carry Either a PIK3CA Mutation or Have PTEN Loss
city
~92 mi. (Jinan, China, +170 more cities)
facility
Novartis Investigative Site
biomarker
ER Negative, +4 more biomarkers
drug
alpelisib, +1 more drug
drug type
chemotherapy, +1 more type